RADX
Radiopharm Theranostics Limited
NASDAQ · Healthcare · Biotechnology · AU
$2.08
−3.48%Margins
Gross margin
-77.7%
EBITDA margin
-2468.6%
EBIT margin
-2468.6%
Net margin
-1992.5%
FCF margin
0.0%
-218.5%
Return on equity
-89.7%
Return on assets
-270.7%
Return on invested capital
0.04x
Asset turnover
-$37.2M
Cash from operations
$0.21
Cash per share
Margins, returns on capital and operating efficiency from the latest trailing period · Data as of Jun 1, 2026